EU Pharma Reform Amendments: More Shortage Reporting Obligations For Companies & Regulators

In the third of a series of articles on the European Parliament’s changes to the planned reform of EU pharmaceutical legislation, the Pink Sheet looks at how the amended proposals on notifying drug shortages could impact companies, regulators and wholesale distributors.